Perbandingan Tingkat Pencapaian Target Tekanan Darah oleh Lisinopril dan Valsartan pada Pasien Stroke Iskemik dengan Faktor Risiko Hipertensi
DOI:
https://doi.org/10.55175/cdk.v45i4.798Keywords:
Lisinopril, target tekanan darah, valsartanAbstract
Hipertensi merupakan salah satu faktor risiko terpenting pada stroke iskemik. Terapi antihipertensi bertujuan mencegah kekambuhan stroke. Tujuan penelitian ini adalah untuk membandingkan tingkat pencapaian tekanan darah antara lisinopril dan valsartan pada pasien stroke iskemik dengan faktor risiko hipertensi di instalasi rawat jalan Rumah Sakit Bethesda Yogyakarta. Jenis penelitian adalah penelitian observasional analitik kohort retrospektif. Data dianalisis univariat dan bivariat dengan uji Chi-square atau uji Fisher. Data 108 pasien hipertensi pasca-stroke iskemik terdiri dari kelompok yang diberi valsartan 81 pasien dan lisinopril 27 pasien. Target tekanan darah yang tercapai pada kelompok valsartan adalah 40 orang (49,4%) dan lisinopril 15 orang (50,9%), tidak berbeda bermakna (p value>0,05). Hasil penelitian menunjukkan tidak terdapat perbedaan dalam mencapai target tekanan darah antara lisinopril dan valsartan pada pasien stroke iskemik dengan faktor risiko hipertensi di instalasi rawat jalan Rumah Sakit Bethesda Yogyakarta.
Hypertension is one of the biggest risk factors for ischemic stroke. The goal of therapy with antihypertensive treatment is to avoid recurrence of stroke. This research compares the rate of blood pressure target achievement between lisinopril and valsartan in ischemic stroke parients with risk factor hypertension at Outpatient Clinic Bethesda Hospital in Yogyakarta. The research is observational retrospective cohort analysis. Data analysis were univariate and bivariate with Chi-square test or Fisher’s exact test. Among 108 post ischemic stroke patients with hypertension, 81 patients received valsartan and 27 patients lisinopril. The target blood pressure was achieved in 40 people (49.4%) in valsartan group and in 15 people (50.9%) in lisinopril group (p value>0.05). No difference in reached target blood pressure between lisinopril and valsartan group in ischemic stroke patients with hypertension at outpatient clinic Bethesda Hospital in Yogyakarta.
Downloads
References
World Health Organization. The WHO STEPwise approach to stroke surveillance. 2006.
Sutrisno A. Stroke? You must know before you get it. Jakarta: PT Gramedia Pustaka Utama; 2007.p. 3, 8 – 10.
World Heath Organization. Q&As on hypertension [Internet]. 2015 [cited 2016 Dec 27]. Available from: http://www.who.int/features/qa/82/en/
Kementerian Kesehatan RI. Riset kesehatan dasar. Jakarta: Bakti Husada; 2013.
Dinas Kesehatan DIY. Profil kesehatan Daerah Istimewa Yogyakarta [Internet]. 2013 [cited 2017 Jan 30]. Available from: http://www.depkes.go.id/resources/download/profil/PROFIL_KES_PROVINSI_2012/14_Profil_Kes.Prov.DIYogyakarta_2012.pdf
Sari W, Indrawati L, Dewi CS. Care yourself stroke. Jakarta: Penebar Plus; 2016 .p. 11-2.
Duricic S, Tamara R., Milorad Z. Risk factors of the first stroke. Med Pregl; LXVII. 2015;(1-2):17-21.
McPhee SJ. Patofisiologi penyakit: Pengantar menuju kedokteran klinis. 5th Edisi. Jakarta: Buku Kedokteran EGC; 2007. p. 341.
Meschia JF, Bushnell C, Albala BB, Braun LT, Bravata DM, Eckel RH, et al. Guideline for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754 – 832.
Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517–84.
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.
Adie K. Clinical guideline for secondary prevention management in stroke. Royal Cornwall Hospital. 2012.
Alfiana Y. Analisis cost-effectiveness kombinasi valsartan-amlodipin dibandingkan lisinopril-amlodipin pada pasien hipertensi rawat jalan di RSUP Dr, Soeradji Tirtonegoro Klaten [Skripsi]. Universitas Islam Indonesia Yogyakarta: Fakultas Matematika dan Ilmu Pengetahuan Alam; 2013.
Dahlan MS. Statistik: Untuk kedokteran dan kesehatan. 6th Edisi. Jakarta: Epidemiologi Indonesia; 2014.
Kabi GYCR, Tumewah R, Kembuan MAHN. Gambaran faktor risiko pada penderita stroke iskemik yang dirawat inap Neurologi RSUP Prof.Dr.R.D.Kandou Manado periode Juli 2012 – Juni 2013. Jurnal e-Clinic. 2015;3(1):457–62.
Usrin I, Mutiara E, Yusad Y. Pengaruh hipertensi terhadap kejadian stroke iskemik dan stroke hemoragik di ruang Neurologi di Rumah Sakit Stroke Nasional (RSSN) Bukittinggi tahun 2011. Jurnal Universitas Sumatera Utara. 2011.
Mancia G, Fagard R, Narkiewickz K, Redon J, Zanchetti A, Bohm M, et al. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-357.
Ramadany AF, Pujarini LA, Candrasari A. Hubungan diabetes melitus dengan kejadian stroke iskemik di RSUD Dr. Moewardi Surakarta. Biomedika. 2013;5(2): 11–6.
Fitrianto H, Azmi S, Kadri H. Penggunaan obat antihipertensi pada pasien hipertensi esensial di poliklinik Ginjal Hipertensi RSUP Dr.M.Djamil tahun 2011. Jurnal Kesehatan Andalas. 2014;3(1):45–8.
Gualtierotti R, Zoppi A, Mugellini A, Derosa G, D’Angelo A, Fogari R. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. Journal Expert Opinion on Pharmacotherapy. 2013;1 (14).
Ratnasari F, Nugroho P. Hubungan jumlah kombinasi obat antihipertensi terhadap kendali tekanan darah pada pasien poliklinik Ginjal dan Hipertensi IPD di RSCM. Jurnal Fakultas Kedokteran Universitas Indonesia. 2013.
Schmieder RE, Ruilope LM. Blood pressure control in patients with comorbidities. The Journal of Clinical Hypertension. 2008;10(8):624–31.
Suhadi R, Atthobari J, Irawan B, Dwiprahasto I. Hubungan faktor komorbiditas, intensifikasi terapi, dan pengendalian tekanan darah. Jurnal Farmasi Sains dan Komunitas. 2013;10(1):1 – 8.
Lumbantobing SM. Stroke: Bencana peredaran di otak. Jakarta: Fakultas Kedokteran Universitas Indonesia; 2013.p. 13.
Sager P, Heilbraun J, Turner JR, Gintant G, Geiger MJ, Kowey PR, et al. Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium. American Heart Journal. 2013;165(4):477–88.
Biaggioni I, Robertson D. Chapter 9: Adrenoceptor agonists and sympathomimetic drugs. Basic and Clinical Pharmacology [Internet]. 2012 [cited 2017 Jan 9]. Availbale from: http://accesspharmacy.mhmedical.com/content.aspx?bookid=388§ionid=45764228.
Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The blood pressure reduction and tolerability of valsartan in comparison with lisinopril (PREVAIL) study. USA: Clinical Therapeutics. 2004;26(6):855–65.
Helmidanaro R. Perbandingan pencapaian target tekanan darah dan renopretektif pada monoterapi angiotensin converting enzyme inhibitor dan angiotensin II receptor blockers di RSUD Abdul Wahab Syahranie Samarinda [Thesis]. MSc. Fakultas Farmasi, Yogyakarta: Universitas Gadjah Mada; 2015.
Black HR, Graff A, Stoltz R, Shute D, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Journal of Human Hypertension. 1997;11(8).
Wahyuningtiyas DA. Analisis efektivitas biaya terapi antihipertensi pada pasien hipertensi rawat inap di Rumah Sakit Umum Daerah Dr. Moewardi tahun 2014. Fakultas Farmasi, Surakarta: Universitas Muhammadiyah Surakarta; 2015.
Agency for Healthcare Research and Quality. Choosing medicines for high blood pressure: A review of the research on ACEIs, ARBs, and DRIs. Effective Health Care Program. 2011;11(12).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
